中国实用外科杂志 ›› 2010, Vol. 30 ›› Issue (04): 247-249.

• 述评 • 上一篇    下一篇

胃肠间质瘤—分子生物学研究实体瘤的先驱

詹文华   

  1. 中山大学附属第一医院, 广东广州 510080
  • 出版日期:2010-04-01 发布日期:2010-04-06

  • Online:2010-04-01 Published:2010-04-06

摘要:

近20年间的研究积累了肉瘤的大量基因资料,为肉瘤的诊治进展打下良好的基础。由于最近的抗kit酪氨酸激酶抑制剂的良好疗效,20世纪以前绝大部分被误称为平滑肌肿瘤、只有手术治疗有效的胃肠间质瘤(GIST)才得到了人们的重视。许多临床试验业已证明,靶向治疗作为GIST的一线、二线治疗,或作为中、高危病人手术后的辅助治疗都是有效的。若取得这样的成就,在其他更常见的肿瘤如乳腺癌或肺癌则需要花上数十年的时间。这些进步应归功于近10年间GIST的细胞来源、发病机理和分子生物学的研究领域取得了突破性进展。参照GIST这种研究模式,我们应该还能开发出其他常见肿瘤的更有效的治疗方法。所以,胃肠间质瘤堪称分子生物学研究实体瘤的先驱。

关键词: 胃肠间质瘤, 发病机理, 分子生物学

Abstract:

GIST is the forerunners of the solid tumor in field of molecular biology research   ZHAN Wen-hua. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
Abstract    A great amount of genetic information for sarcomas has been accumulated during the past two decades by which the progress of diagnoses and treatments was underpinned. GIST has become well known recently because of the effectiveness of anti-KIT tyrosine kinase inhibitors. From a disease that 10 years ago was named as leiomyoma or and was only treatable with surgery, now many trials have identified active first-line systemic therapy, an active second-line agent, and established the role of adjuvant therapy after surgery for patients with intermediate- and high-risk tumors. Those are accomplishments that need take decades to achieve for other more common diseases such as breast cancer or lung cancer. The progress in GIST has come directly from the breakthrough that have been made in its cell origin, etiology and pathogenesis. By studying model diseases such as GIST, it should be able to develop paradigms to treat more common cancers as well. For the reason, GIST is the forerunners of the solid tumor in field of molecular biology research.

Key words:  GIST, pathogenesis;molecular biology